206 related articles for article (PubMed ID: 33574356)
21. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P
Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712
[TBL] [Abstract][Full Text] [Related]
22. Targeted inhibition of c-MET by podophyllotoxin promotes caspase-dependent apoptosis and suppresses cell growth in gefitinib-resistant non-small cell lung cancer cells.
Oh HN; Kwak AW; Lee MH; Kim E; Yoon G; Cho SS; Liu K; Chae JI; Shim JH
Phytomedicine; 2021 Jan; 80():153355. PubMed ID: 33039730
[TBL] [Abstract][Full Text] [Related]
23. Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors.
Mortazavi M; Divar M; Damghani T; Moosavi F; Saso L; Pirhadi S; Khoshneviszadeh M; Edraki N; Firuzi O
Front Chem; 2022; 10():969559. PubMed ID: 36465863
[TBL] [Abstract][Full Text] [Related]
24. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
Li S; Zhao Y; Wang K; Gao Y; Han J; Cui B; Gong P
Bioorg Med Chem; 2013 Jun; 21(11):2843-55. PubMed ID: 23628470
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
Zhao Y; Zhang J; Zhuang R; He R; Xi J; Pan X; Shao Y; Pan J; Sun J; Cai Z; Liu S; Huang W; Lv X
Bioorg Med Chem; 2017 Jun; 25(12):3195-3205. PubMed ID: 28412159
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, anticancer, and docking studies of salicyl-hydrazone analogues: A novel series of small potent tropomyosin receptor kinase A inhibitors.
Alam MS; Choi SU; Lee DU
Bioorg Med Chem; 2017 Jan; 25(1):389-396. PubMed ID: 27856237
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y
Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664
[TBL] [Abstract][Full Text] [Related]
28. Novel spiroindoline quinazolinedione derivatives as anticancer agents and potential FLT3 kinase inhibitors.
Divar M; Edraki N; Damghani T; Moosavi F; Mohabbati M; Alipour A; Pirhadi S; Saso L; Khabnadideh S; Firuzi O
Bioorg Med Chem; 2023 Jul; 90():117367. PubMed ID: 37348260
[TBL] [Abstract][Full Text] [Related]
29. Novel [1,2,4] Triazol [4,3-a] Pyridine Derivatives as Potential Selective c-Met Inhibitors with Improved Pharmacokinetic Properties.
Zhao J; Gou S; Zhang X; Liang Y; Fang L
Anticancer Agents Med Chem; 2017; 17(8):1102-1112. PubMed ID: 27804848
[TBL] [Abstract][Full Text] [Related]
30. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer.
El Fitori J; Su Y; Büchler P; Ludwig R; Giese NA; Büchler MW; Quentmeier H; Hines OJ; Herr I; Friess H
Cancer; 2007 Oct; 110(7):1457-68. PubMed ID: 17676584
[TBL] [Abstract][Full Text] [Related]
31. New Approaches for the Synthesis of Heterocyclic Compounds Corporating Benzo[d]imidazole as Anticancer Agents, Tyrosine, Pim-1 Kinases Inhibitions and their PAINS Evaluations.
Mohareb RM; Milad YR; Mostafa BM; El-Ansary RA
Anticancer Agents Med Chem; 2021; 21(3):327-342. PubMed ID: 32698742
[TBL] [Abstract][Full Text] [Related]
32. Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer.
Takiguchi S; Inoue K; Matsusue K; Furukawa M; Teramoto N; Iguchi H
Int J Oncol; 2017 Jul; 51(1):184-192. PubMed ID: 28498406
[TBL] [Abstract][Full Text] [Related]
33. Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for 'Off-Target' Effects Not Mediated by c-Met Inhibition.
Reuther C; Heinzle V; Spampatti M; Vlotides G; de Toni E; Spöttl G; Maurer J; Nölting S; Göke B; Auernhammer CJ
Neuroendocrinology; 2016; 103(3-4):383-401. PubMed ID: 26338447
[TBL] [Abstract][Full Text] [Related]
34. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
35. Discovery of thinopyrimidine-triazole conjugates as c-Met targeting and apoptosis inducing agents.
Wang L; Xu S; Liu X; Chen X; Xiong H; Hou S; Zou W; Tang Q; Zheng P; Zhu W
Bioorg Chem; 2018 Apr; 77():370-380. PubMed ID: 29421713
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
[TBL] [Abstract][Full Text] [Related]
37. Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors.
Tang Q; Zhang G; Du X; Zhu W; Li R; Lin H; Li P; Cheng M; Gong P; Zhao Y
Bioorg Med Chem; 2014 Feb; 22(4):1236-49. PubMed ID: 24485123
[TBL] [Abstract][Full Text] [Related]
38. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
[TBL] [Abstract][Full Text] [Related]
39. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
Nan X; Li HJ; Fang SB; Li QY; Wu YC
Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and molecular docking study of 3H-imidazole[4,5-c]pyridine derivatives as CDK2 inhibitors.
Wu YZ; Ying HZ; Xu L; Cheng G; Chen J; Hu YZ; Liu T; Dong XW
Arch Pharm (Weinheim); 2018 Jun; 351(6):e1700381. PubMed ID: 29708285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
